U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 65 - 80 of 7004 results

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (RACEMIC)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (RACEMIC)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (RACEMIC)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (UNKNOWN)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (MIXED)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (RACEMIC)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (UNKNOWN)



Description

Edatrexate (10-ethyl-10-deazaaminopterin or 10-EDAM) is an analog of methotrexate with improved pre-clinical antitumor activity, more selective cellular uptake, and with the more extensive formation of intracellular polyglutamate metabolites. This drug is a new dihydrofolate reductase inhibitor, which was studied in phase II clinical trial for the patients with different cancers. The studies were discontinued, for example, in advanced renal cell carcinoma edatrexate in the investigated dose and schedule had minimal activity and was toxic. In case of non-small-cell lung cancer, the dosing schedule of edatrexate did not appear to be improved compared to other chemotherapeutic regimens. In addition, edatrexate was involved in the experiment for the treatemnt of rheumatoid arthritis, but this study was also discontinued.
Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
USAN/INN

Class (Stereo):
CHEMICAL (ABSOLUTE)